Characteristic | Category | Number of papers | Percentage |
---|---|---|---|
(%) | |||
Targeting population | China (mainland) | 213 | 27 |
Japan | 164 | 20.8 | |
Thailand | 73 | 9.3 | |
Korea | 58 | 7.4 | |
Hong Kong | 56 | 7.1 | |
Taiwan | 54 | 6.8 | |
Singapore | 46 | 5.8 | |
Iran | 34 | 4.3 | |
India | 20 | 2.5 | |
Malaysia | 18 | 2.3 | |
Othersa | 53 | 6.7 | |
Type of intervention | Screening or diagnosis | 102 | 12.9 |
Prevention (e.g. vaccination/public intervention) | 96 | 12.2 | |
Therapy (e.g. surgery/pharmaceutical) | 576 | 73 | |
Disease management | 14 | 1.8 | |
Other (diabetes pay-for-performance program) | 1 | 0.1 | |
Study perspective | Patient | 14 | 1.8 |
Provider/payer | 426 | 54 | |
Societal | 249 | 31.6 | |
Not reported | 100 | 12.7 | |
Time horizon | Less than 1 year | 27 | 3.4 |
1–5 years | 112 | 14.2 | |
6-10 years | 62 | 7.9 | |
More than 10 years | 410 | 52 | |
Not reported | 178 | 22.6 | |
Type of model | Markov models | 418 | 53 |
Decision tree models | 99 | 12.5 | |
Both | 85 | 10.8 | |
Other | 70 | 8.9 | |
Type of sensitivity analysis | None | 69 | 8.7 |
Non-probabilistic one/multi way sensitivity analysis | 229 | 29.1 | |
Probabilistic sensitivity analysis | 491 | 62.2 | |
Discount rate used for cost | None | 177 | 22.4 |
1%-2% | 32 | 4 | |
3% | 446 | 56.5 | |
3.5%-7.2% | 134 | 17 | |
Discount rate used for outcome | None | 177 | 22.4 |
1%-2% | 34 | 4.3 | |
3% | 450 | 57 | |
3.5%-7.2% | 128 | 16.2 | |
Identification of HSUs | Systematic review | 19 | 2.4 |
Non-systematic review | 21 | 2.7 | |
Not reported | 749 | 94.9 |